中信建投指出，医疗器械板块涨跌较多的部分个股预计与Q3业绩披露等因素有关。短期来看，建 议把握2026年业绩改善个股的业绩和估值修复机会，多家医疗器械行业细分赛道龙头公司将于2026年迎 来加速增长。长期来看，医疗器械行业投资机会来自创新、出海和并购整合，板块的创新和国际化能力 得到认可、估值正在被重估。 相关ETF全称：华夏中证全指医疗器械ETF（562600），联接基金(A类:021250、C类:021251) 每日经济新闻 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 昨日，A股市场探底回升，三大指数全线翻红。截至收盘，沪指涨0.55%。盘面上，医药板块整体 维持震荡态势。相关ETF方面，医疗器械ETF（562600）微跌0.11%，单日逆势吸金超千万，已连续5交 易日获得资金净流入，合计超3千万，占成交额比例高达40%，显示资金逢低布局意图明显。 消息面，11月3日202 ...

Core Viewpoint - The A-share market experienced fluctuations last week, with the Shanghai Composite Index showing a slight increase of 0.11%. There was a rise in risk-averse sentiment, leading to gains in sectors such as pharmaceuticals, film, and medical devices. The medical device ETF (562600) saw a net inflow of 20 million over five days, accounting for 29.19% of its trading volume. The "14th Five-Year Plan" emphasizes support for innovative drugs and medical devices, aiming to drive economic growth through breakthroughs in key technologies in biomanufacturing and brain-computer interfaces. This strategic arrangement aligns the pharmaceutical industry's upgrade with national economic optimization, promoting higher quality development in the sector. Looking ahead, overseas markets show advantages in price stability and healthcare payment, with leading medical device companies experiencing faster growth abroad compared to the domestic market. The focus in the domestic market is shifting towards high-barrier innovation sectors, with policies supporting AI and brain-computer interface products, which will catalyze the commercialization of new products [1]. Group 1 - The A-share market showed a slight increase of 0.11% last week, with fluctuations observed [1] - Medical device ETF (562600) received a net inflow of 20 million, representing 29.19% of its trading volume [1] - The "14th Five-Year Plan" emphasizes support for innovative drugs and medical devices, aiming for breakthroughs in key technologies [1] Group 2 - Overseas markets exhibit advantages in price stability and healthcare payment, with leading companies growing faster abroad [1] - The domestic market is shifting focus to high-barrier innovation sectors, supported by policies for AI and brain-computer interface products [1]